WO2010117727A3 - Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions - Google Patents

Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions Download PDF

Info

Publication number
WO2010117727A3
WO2010117727A3 PCT/US2010/029056 US2010029056W WO2010117727A3 WO 2010117727 A3 WO2010117727 A3 WO 2010117727A3 US 2010029056 W US2010029056 W US 2010029056W WO 2010117727 A3 WO2010117727 A3 WO 2010117727A3
Authority
WO
WIPO (PCT)
Prior art keywords
posiphen
phenserine
neurodegenerative conditions
treating neuropsychiatric
treating
Prior art date
Application number
PCT/US2010/029056
Other languages
French (fr)
Other versions
WO2010117727A2 (en
Inventor
Jack Rogers
Rudolph E. Tanzi
Robert Moir
Nigel Greig
Avi L. Friedlich
Original Assignee
The General Hospital Corporation
National Institute Of Aging Office Of Technology Transfer, National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, National Institute Of Aging Office Of Technology Transfer, National Institutes Of Health filed Critical The General Hospital Corporation
Publication of WO2010117727A2 publication Critical patent/WO2010117727A2/en
Publication of WO2010117727A3 publication Critical patent/WO2010117727A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described are methods for treating synucleinopathy in a subject, by administering to the subject a therapeutically effective dose of one or both of POSIPHEN and phenserine.
PCT/US2010/029056 2009-03-30 2010-03-29 Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions WO2010117727A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16472909P 2009-03-30 2009-03-30
US61/164,729 2009-03-30

Publications (2)

Publication Number Publication Date
WO2010117727A2 WO2010117727A2 (en) 2010-10-14
WO2010117727A3 true WO2010117727A3 (en) 2011-03-03

Family

ID=42936798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/029056 WO2010117727A2 (en) 2009-03-30 2010-03-29 Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions

Country Status (1)

Country Link
WO (1) WO2010117727A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
WO2017214197A1 (en) * 2016-06-06 2017-12-14 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272804A1 (en) * 2004-06-08 2005-12-08 Axonyx, Inc Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
US20060018839A1 (en) * 2002-05-17 2006-01-26 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070049576A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018839A1 (en) * 2002-05-17 2006-01-26 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20050272804A1 (en) * 2004-06-08 2005-12-08 Axonyx, Inc Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
US20070049576A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ATSUSHI TAKEDA ET AL.: "Mechanisms of Neuronal Death in Synucleinopathy. Art. 19365", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY., vol. 2006, 2006, pages 1 - 4 *

Also Published As

Publication number Publication date
WO2010117727A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2012062925A3 (en) Compounds and methods for treating pain
WO2011133521A3 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
WO2009089494A3 (en) Pharmaceutical compositions
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
WO2014012094A3 (en) Tetracycline compounds for treating neurodegenerative disorders
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2013056148A3 (en) Scd1 antagonists for treating cancer
PT2740793T (en) Drug composition for cancer treatment and/or prevention
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2249861A4 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2013098416A3 (en) Pain relief compounds
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
EP2776042A4 (en) Combination drug therapy for the treatment of solid tumors
EP2720708A4 (en) Targeting the neuromuscular junction for treatment
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
WO2014031732A3 (en) Methods for inhibiting fascin
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
WO2013025939A9 (en) Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2010149357A3 (en) Methods of using corticotropin-releasing factor for the treatment of cancer
WO2010083208A9 (en) Treating neuropsychiatric diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762150

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762150

Country of ref document: EP

Kind code of ref document: A2